Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms

Clinical Infectious Diseases

Volumn 55, Issue 1, 2012, Pages

  Treviño, Ana ^a   Lopez, Mariola ^a   Vispo, Eugenia ^a   Aguilera, Antonio ^b   Ramos, Jose M ^c   Benito, Rafael ^d   Roc, Lourdes ^e   Eiros, Jose M ^f   De Mendoza, Carmen ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL DE CONXO   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD DISEASE; TROPICAL SPASTIC PARAPARESIS; VIRUS CARRIER; VIRUS LOAD;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CARRIER STATE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; ODDS RATIO; PARAPARESIS, TROPICAL SPASTIC; POLYMORPHISM, GENETIC; SPAIN;

EID: 84862180818     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis343     Document Type: Article

References (22)

1. Poiesz B, Ruscetti F, Gazdar A, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77:7415-9.
2. Hlela C, Shepperd S, Khumalo N, Taylor G. The prevalence of human T-cell lymphotropic virus type 1 in the general population is unknown. AIDS Rev 2009; 11:205-14.
3. Watanabe T. Current status of HTLV-1 infection. Int J Hematol 2011; 94:430-4.
4. Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type 1 infection. Lancet 1999; 353:1951-8.
5. Goncalves D, Proietti F, Ribas J, et al. Epidemiology, treatment and prevention of HTLV-1-associated diseases. Clin Microbiol Rev 2010; 23:577-89.
6. Proietti F, Carneiro-Proietti A, Catalan-Soares B, Murphy E. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24:6058-68.
7. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4:586-93.
8. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type 1 (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 2010; 116:1211-9.
9. Grassi M, Olavarria V, Kruschewsky Rde A, et al. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol 2011; 83:1269-74.
10. Oliere S, Douville R, Sze A, Belnaoui S, Hiscott J. Modulation of innate immune responses during HTLV-1 pathogenesis. Cytokine Growth Factor Rev 2011; 22:197-210.
11. Martin F, Taylor G. Prospects for the management of human T-cell lymphotropic virus type 1-associated myelopathy. AIDS Rev 2011; 13:161-70.
12. Ge D, Fellay J, Thompson J, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
13. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure-a genome wide association study. Gastroenterology 2010; 138:1338-45.
14. Livak K. Allelic discrimation using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14:143-9.
15. Andrade R, Ribeiro M, Namen-Lopes M, et al. Evaluation of the use of real-time PCR for HTLV-1 and-2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop 2010; 43:111-5.
16. Toro C, Rodés B, Poveda E, et al. Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type 1 from a single donor. Transplantation 2003; 75:102-4.
17. Furtado S, Andrade R, Romanelli L, et al. Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease. J Med Virol 2012; 84:664-71.
18. Soriano V, Poveda E, Vispo E, Labarga P, Rallón N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemother 2012; 67:523-9.
19. Thomas D, Thio C, Martin M, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
20. Donnelly R, Dickensheets H, O'Brien T. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 2011; 32:443-50.
21. Macchi B, Balestrieri E, Ascolani A, et al. Susceptibility of primary HTLV-1 isolates from patients with HTLV-1-associated myelopathy to reverse transcriptase inhibitors. Viruses 2011; 3:469-83.
22. Treviño A, Parra P, Bar-Magen T, Garrido C, de Mendoza C, Soriano V. Antiviral effect of raltegravir on HTLV-1 carriers. J Antimicrob Chemother 2012; 67:218-21.